Business Description
CHO Pharma Inc
ISIN : TW0006586001
Description
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 443.46 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1.5 | |||||
| 3-Year EPS without NRI Growth Rate | 0.4 | |||||
| 3-Year FCF Growth Rate | -1.3 | |||||
| 3-Year Book Growth Rate | 9.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.06 | |||||
| 9-Day RSI | 43.77 | |||||
| 14-Day RSI | 43.78 | |||||
| 6-1 Month Momentum % | -21.56 | |||||
| 12-1 Month Momentum % | -38.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.93 | |||||
| Quick Ratio | 24.93 | |||||
| Cash Ratio | 24.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 | |||||
| Shareholder Yield % | 0.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -16.16 | |||||
| ROA % | -15 | |||||
| ROIC % | -54.06 | |||||
| ROC (Joel Greenblatt) % | -2246.22 | |||||
| ROCE % | -16.12 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.9 | |||||
| Price-to-Tangible-Book | 4.56 | |||||
| EV-to-EBIT | -29.4 | |||||
| EV-to-EBITDA | -32.4 | |||||
| EV-to-FCF | -31.13 | |||||
| Price-to-Net-Current-Asset-Value | 4.58 | |||||
| Price-to-Net-Cash | 4.66 | |||||
| Earnings Yield (Greenblatt) % | -3.4 | |||||
| FCF Yield % | -2.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CHO Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | |||
| EPS (TTM) (NT$) | -1.6 | ||
| Beta | -0.04 | ||
| Volatility % | 24.81 | ||
| 14-Day RSI | 43.78 | ||
| 14-Day ATR (NT$) | 1.821965 | ||
| 20-Day SMA (NT$) | 54.695 | ||
| 12-1 Month Momentum % | -38.28 | ||
| 52-Week Range (NT$) | 51.7 - 90.6 | ||
| Shares Outstanding (Mil) | 214.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CHO Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CHO Pharma Inc Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
CHO Pharma Inc Frequently Asked Questions
What is CHO Pharma Inc(ROCO:6586)'s stock price today?
The current price of ROCO:6586 is NT$54.20. The 52 week high of ROCO:6586 is NT$90.60 and 52 week low is NT$51.70.
When is next earnings date of CHO Pharma Inc(ROCO:6586)?
The next earnings date of CHO Pharma Inc(ROCO:6586) is .
Does CHO Pharma Inc(ROCO:6586) pay dividends? If so, how much?
CHO Pharma Inc(ROCO:6586) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers